AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer’s Dementia

First and only clinical trial to reduce hippocampal overactivity during aMCI, the pre-dementia stage of Alzheimer’s disease Restored brain function to pre-disease levels and significantly improved memory BALTIMORE, MD March 11, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia stage of…